Decision: Favourable
Study Title:
A Phase 3, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
NREC Code:
21-NREC-CT-013
Decision:
Favourable
Meeting Date:
07/07/2021
Study Type:
CT application
Principal Investigator:
Dr Patrick Hayden
PI Institution:
St James' Hospital
Sponsor:
Celgene Corporation